Prospective Follow-up After MVA-BN Booster Vaccination

Prospective On-site Study for the Immunological Follow-up of Individuals Who Received Booster Vaccination With MVA-BN Against Mpox

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07342829

Acronym

POQS-Boosted

Enrollment

Registered

2026-01-15

Start date

2026-01-15

Completion date

2028-06-30

Last updated

2026-01-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Monkeypox (Mpox)

Keywords

mpox, immunology, vaccination, booster

Brief summary

POQS-Boosted is a prospective observational study during which individuals who received Booster vaccination against mpox with the MVA-BN vaccine will be invited to provide biological samples at multiple times over the course of two years.

Detailed description

Mpox caused a worldwide outbreak in 2022 and continues to circulate worldwide and causes sporadic cases in Belgium and elsewhere. In the last 10 days, the first cases infected with the probably more virulent clade Ib MPXV have been reported from men who have sex with men in Belgium, the Netherlands, and elsewhere, indicating circulating this viral clade in sexual networks. In Belgium, vaccination against mpox was ceased at the end of 2022 and evidence showed that antibody levels against MPXV have decreased since then, raising questions about sustained protectiveness and the potential for a new mpox outbreak to emerge. POQS-Boosted is a prospective observational study during which individuals who received Booster vaccination against mpox with the MVA-BN vaccine will be invited to provide biological samples at multiple times over the course of two years.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

1. Is scheduled to receive a booster dose of MVA-BN 2. ≥18 years 3. Willingness to provide written informed consent 4. Willingness to follow the study schedule

Exclusion criteria

1\. Past or current MPXV infection

Design outcomes

Primary

Measure	Time frame	Description
Orthopoxvirus-specific serum binding and neutralising antibody titre	from enrollment to the end of follow up at 2 years	To describe the evolution of the orthopoxvirus-specific serum antibody response up to two years after MVA-BN booster vaccination

Secondary

Measure	Time frame	Description
Orthopoxvirus-specific systemic T- and B cell-mediated immune responses to MPXV	from enrollment up to 2 years	To describe the evolution of the orthopoxvirus-specific systemic cellular immune response up to two years after MVA-BN booster vaccination
MPXV-specific IgA in saliva and anorectal samples; T and B cell-mediated immune responses to MPXV, measured on saliva and anorectal samples	from enrolment up to two years	To describe the evolution of the orthopoxvirus-specific mucosal antibody \& cellular immune response up to two years after MVA-BN booster vaccination

Countries

Belgium

Contacts

CONTACTChristophe Van Dijck, PhD

cvandijck@itg.be+32 3 345 58 65

CONTACTClinical Trials Unit Antwerp

studies@itg.be+32 3 247 66 66

PRINCIPAL_INVESTIGATORLaurens Liesenborghs, MD

Institute of Tropical Medicine Antwerp

Outcome results